Skip to main content
Explore URMC
menu

Eric J. Huselton, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 273-1042

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Cancer

Biography

Dr. Eric Huselton received his medical degree from SUNY Downstate College of Medicine in 2012. He completed an Internal Medicine Residency Training Program and a Hematology/Oncology Fellowship at Washington University in Saint Louis/Bames Jewish Hospital in 2015 and 2018, respectively. Dr. Huselton is certified by the American Board of Internal Medicine.

Dr. Huselton is an Assistant Professor in the Division of Hematology and Oncology at the University of Rochester School of Medicine and Dentistry.

Dr. Huselton's special interests include allogenic hematopoietic cell transplant, haploidentical hematopoietic cell transplant, AML, MDS and hematologic malignancies. He aims to provide the best care by incorporating new treatments based on the most recent data, including clinical trials, targeted therapies, immunotherapy and cellular therapies. Dr. Huselton's hobbies include sailing, hiking and cooking.

Credentials

Specialties

  • Hematology - American Board of Internal Medicine
  • Internal Medicine - American Board of Internal Medicine
  • Medical Oncology - American Board of Internal Medicine

Education

2012
MD | SUNY Downstate Medical Center College of Nursing

Post-doctoral Training & Residency

07/01/2015 - 06/30/2018
Fellowship in Hematology & Oncology at Washington University Dept of Ophthalmology-GME

07/01/2013 - 06/30/2015
Residency in Internal Medicine at Washington University in St. Louis

06/01/2012 - 06/30/2013
Internship in Internal Medicine at Washington University in St. Louis

VIEW ALL expand_more

Awards

2019 - 2022
Wilmot Fellowship Award
Sponsor: Wilmot Cancer Institute
Location: Rochester, NY

2016
Travel Award, Society of Hematologic Oncology

2012
Harold A. Lyons Award for Excellence in Clinical Medicine

2011
Alpha Omega Alpha
Location: SUNY Downstate College of Medicine

2009
Downstate Alumni Summer Research Fellow

VIEW ALL expand_more

Clinical Trials

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Lead Researcher: Eric J Huselton

The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is expected based on historical controls. The investigators will also prospectively determine the relapse-free and overall survival of patients who have not cleared their mutations. Because the relapse rate of patients with persistent mutations is expected to be high, treatment with either standard of care consolidation therapy alone or alloSCT will be permitted, at the discretion of the treating physician.

View Study Details

Publications

Journal Articles

12/20/2021
Loh KP, Sanapala C, Janelsins M, Klepin HD, Schnall R, Culakova E, Sohn MB, Vertino P, Susiarjo M, Jensen-Battaglia M, Becker MW, Liesveld J, Mendler JH, Huselton E, Lin PJ, Mustian K. "Protocol for a pilot randomized controlled trial of a mobile health exercise intervention for older patients with myeloid neoplasms (GO-EXCAP 2)." Journal of geriatric oncology.. 2021 Dec 20; Epub 2021 Dec 20.

11/18/2021
Eastburg L, Russler-Germain DA, DiPersio JF, Fountaine T, Andolina JR, Abboud R, Huselton E. "Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide." Leukemia & lymphoma.. 2021 Nov 18; :1-5. Epub 2021 Nov 18.

9/22/2021
Huselton E, Rettig MP, Campbell K, Cashen AF, DiPersio JF, Gao F, Jacoby MA, Pusic I, Romee R, Schroeder MA, Uy GL, Marcus S, Westervelt P. "Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS." Leukemia research.. 2021 Sep 22; 110:106713. Epub 2021 Sep 22.

VIEW ALL PUBLICATIONS